Skip to main content
Clinical Trials/NCT06382480
NCT06382480
Recruiting
Not Applicable

Meal Timing-based Strategies to Improve Glucose Metabolism in Prediabetes and Type 2 Diabetes

German Institute of Human Nutrition1 site in 1 country30 target enrollmentApril 12, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Overweight
Sponsor
German Institute of Human Nutrition
Enrollment
30
Locations
1
Primary Endpoint
Mean 24-hour glucose
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

The overall aim is to identify the dietary pattern for prevention and treatment of type 2 diabetes. The specific aim of this pilot project is to compare effects of two diets with different diurnal distribution of carbohydrates and protein on the glucose metabolism in subjects with prediabetes and type 2 diabetes and its effects on inflammatory status.

Detailed Description

Overweight individual with prediabetes and non-insulin treated type 2 diabetes will be recruited for the study. The trial will have a cross-over design and compare metabolic effects of two isocaloric 4-week interventions with opposite timely distribution of macronutrient intake - a high-protein (HP) breakfast and a high-carb (HC) dinner (HP/HC intervention) vs. a HC breakfast and a HP dinner (HC/HP intervention) - divided by a 4-week wash-out phase. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10E%protein, 60%E carbs, and 30%E fat.

Registry
clinicaltrials.gov
Start Date
April 12, 2024
End Date
February 28, 2027
Last Updated
8 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Olga Ramich (formerly Pivovarova)

Head of Research Group Molecular Nutritional Medicine

German Institute of Human Nutrition

Eligibility Criteria

Inclusion Criteria

  • Prediabetes (fasting blood sugar 100-125 mg/dl)
  • Diabetes type 2 (fasting blood sugar \>126 mg/dl)
  • Overweight and obesity (BMI 25-50 kg/m2)

Exclusion Criteria

  • Other diabetes types
  • Insulin treatment
  • Shift work
  • Weight changes \>5% within past 3 months
  • Systemic glucocorticoid therapy
  • Systemic infections
  • Severe anemia
  • High blood pressure (\>180/110 mmHg)
  • Endocrinologic, liver and heart disorders
  • Immune diseases

Outcomes

Primary Outcomes

Mean 24-hour glucose

Time Frame: 4 weeks

Mean 24-hour glucose assessed by continuous glucose monitoring (CGM)

Secondary Outcomes

  • Measurement of body weight(4 weeks)
  • Renal values (creatinine, urea, uric acid)(4 weeks)
  • Intra- und inter-day glycemic variability(4 weeks)
  • Inflammatory markers and T cell populations analyses(4 weeks)
  • Waist and hip circumference / waist to hip ratio(4 weeks)
  • Systolic and diastolic blood pressure(4 weeks)
  • Energy expenditure and substrate oxidation rates(4 weeks)
  • Measurement of height(4 weeks)
  • Body fat and lean mass(4 weeks)
  • Gene expression in peripheral blood mononuclear cells (PBMC)(4 weeks)
  • Glucose levels in meal tolerance test (MTT)(4 weeks)
  • Metabolic hormones (insulin, C-peptide, glucagon, glucagon-like peptite 1(GLP-1), gastric inhibitory polypeptide (GIP), peptide YY (PYY), ghrelin, adiponectin, leptin)(4 weeks)
  • Hepatic values (gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT))(4 weeks)
  • Physical activity(4 weeks)
  • Adipose tissue transcriptome(4 weeks)
  • Satiety and hunger scores(4 weeks)
  • Sleep/wake timing and sleep quality(4 weeks)
  • Gut microbiota and microbiome-derived metabolites(4 weeks)
  • Determination of decision behavior(4 weeks)

Study Sites (1)

Loading locations...

Similar Trials